Whalesbook
Torrent Pharmaceuticals ne FY26 ke Q4 mein kamaal ka revenue growth dikhaya hai, khaas kar India aur Brazil jaise key markets mein zabardast sales ke karan. Lekin, revenue badhne ke bawajood, company ka net profit pichhle saal ke comparison mein kam ho gaya.
Margin Pressure Ne Profitability Ko Dabaya
March 31, 2026 ko khatam hue Q4 mein, Torrent Pharma ka net profit ₹389 crore raha, jo pichhle saal ke ₹498 crore se 21.9% kam hai. Revenue 41.8% badh kar ₹4,197 crore pahunch gaya. EBITDA bhi 40.7% badh kar ₹1,356 crore hua, lekin EBITDA margin thoda sa 32% se 33% tak gir gaya. Yeh chhota sa dip operational costs badhne ya pricing issues ko bata raha hai, jo company ke liye ek chinta ka vishay ho sakta hai, kyunki woh ek badi capital raise ki taiyari kar rahe hain. Company ka stock BSE par ₹4,494.00 par band hua, jo din mein 0.52% upar tha.
Key Markets Mein Mazboot Performance
Domestic business ne sabse zyada help kiya, jahan revenue 43% badh kar ₹2,215 crore ho gaya, jo Indian Pharmaceutical Market ke 10% growth se kaafi zyada hai. Torrent ka base business 15% grow kiya aur naye Gx Semaglutide product ne 38% market share pakad li. International markets mein, Brazil ka revenue 30% badh kar ₹455 crore aur US market mein 31% growth ke saath ₹396 crore raha. Germany ka revenue 16% badh kar ₹333 crore raha, halanki constant currency revenue supply chain issues ke karan thoda kam hua.
Pure FY26 ke liye, Torrent Pharma ka total revenue ₹15,733 crore tha, aur net profit ₹1,556 crore raha, jo pichhle saal se 11.4% kam hai.
Capital Raise Aur Shareholder Returns
Torrent Pharmaceuticals apne shareholders se ₹5,000 crore tak raise karne ke liye Qualified Institutional Placement (QIP) ki approval maang rahi hai. Ye paisa future expansion aur strategic initiatives ke liye use hoga. Company ne FY26 ke liye ₹9 per equity share ka final dividend bhi propose kiya hai, jo ₹29 per share ke interim dividend ke alawa hai. Ye capital raise ambitious growth plans ko dikhata hai, lekin revenue performance ko dekhte hue external funding ki zarurat par sawaal utha raha hai.
Risks Aur Competitive Landscape
Revenue growth ke bawajood EBITDA margin mein hui chhoti si kami ek bada risk hai, jo cost management ya pricing power mein challenges bata rahi hai. Proposed ₹5,000 crore QIP se shareholder dilution ka risk bhi hai. Sun Pharmaceutical Industries aur Cipla jaise competitors bhi achha growth dikha rahe hain, lekin unke EBITDA margins zyada rehte hain, lagbhag 20-25% ke aas-paas. Yeh comparison Torrent Pharma ke liye sector-specific pressures ya internal cost issues ko highlight karta hai, jo QIP ke long-term value ko affect kar sakta hai.
Future Outlook
Torrent Pharmaceuticals ka alag-alag markets mein presence aur product pipeline, jisme Gx Semaglutide ka successful launch bhi shamil hai, use aage bhi revenue growth ke liye position karta hai. Lekin, profit margins ko improve karna shareholder value badhane ke liye bahut important hoga. Company ki operational costs ko manage karne aur competitive market mein naye products ko integrate karne ki ability ko analysts closely watch karenge.